Supriya LifescienceNSE:SUPRIYA -2.32%82 Pretax Margin % is 33.32% as of Mar. 2026, which is 4% above its 10-year median of 32.04. GuruFocus rates NSE:SUPRIYA with a GF Score™ of 82/100 and a GF Value™ of ₹809.53 (Fairly Valued). The stock has 3 warning signs investors should review. Among 941 Biotechnology companies, Supriya Lifescience ranks better than 91.5% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Supriya Lifescience Pretax Margin % Related Terms
Supriya Lifescience Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Supriya Lifescience's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SUPRIYA vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Supriya Lifescience's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supriya Lifescience Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Supriya Lifescience's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Supriya Lifescience's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supriya Lifescience (NSE:SUPRIYA) has a Pretax Margin % of 33.32% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Supriya Lifescience and its competitors. This is near median its historical median of 32.04. Over the past decade, Supriya Lifescience's Pretax Margin % has ranged from 20.55 to 43.42. According to the industry distribution chart, Supriya Lifescience ranks #80 out of 941 companies in the Biotechnology industry, placing it in the top 8.5%.
Is Supriya Lifescience's Pretax Margin % too high?
Supriya Lifescience's current Pretax Margin % of 33.32% is near median its 10-year median of 32.04. Over the past 10 years, this metric has ranged from a low of 20.55 to a high of 43.42. Based on the distribution chart, Supriya Lifescience ranks #80 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Supriya Lifescience has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supriya Lifescience's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Supriya Lifescience ranks #80 out of 941 companies for Pretax Margin %. This places Supriya Lifescience in the top 9% of its industry — outperforming the majority of peers. Historically, Supriya Lifescience's own Pretax Margin % has ranged from 20.55 to 43.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Supriya Lifescience and its competitors. Supriya Lifescience's current Pretax Margin % is 33.32%, which is near median its own 10-year median of 32.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supriya Lifescience stock overvalued right now?
Based on GuruFocus' analysis, Supriya Lifescience (NSE:SUPRIYA) is currently considered Fairly Valued. The stock's GF Value™ is ₹809.53, compared to a current price of ₹854.60 — trading 5.6% above its estimated fair value. The current Pretax Margin % is 33.32%, which is near median its 10-year median of 32.04. Supriya Lifescience's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Supriya Lifescience (NSE:SUPRIYA), the current Pretax Margin % is 33.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supriya Lifescience (NSE:SUPRIYA) Overvalued in 2026?
Based on GuruFocus' analysis, Supriya Lifescience stock appears to be overvalued.
The current stock price of ₹854.60 is trading 5.6% above its estimated GF Value™ of ₹809.53.
GuruFocus considers Supriya Lifescience to be Fairly Valued.
Key valuation signals for NSE:SUPRIYA:
Pretax Margin %: 33.32% (near median its 10-year median of 32.04)
GF Value™: ₹809.53 vs. price of ₹854.60 (5.6% above fair value)
No single metric tells the full story. See the NSE:SUPRIYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
82GF Score
Get the complete analysis for NSE:SUPRIYA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUPRIYA has been successfully added to your 
